{
    "title": "Immunomedics in $2 bln licensing deal with Seattle Genetics",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4211768/Immunomedics-2-bln-licensing-deal-Seattle-Genetics.html",
    "date": "2017-02-10",
    "keywords": [
        "drug",
        "deal",
        "cancer",
        "percent",
        "seattle",
        "licensing",
        "gmt",
        "divya",
        "development",
        "path",
        "trial",
        "application",
        "approval",
        "part",
        "bln",
        "email",
        "groverfeb",
        "developer",
        "inc",
        "friday",
        "morning",
        "revenue",
        "thursday",
        "immu132",
        "cash",
        "paymentthe",
        "stage",
        "study",
        "breast",
        "disease",
        "food",
        "status",
        "basis",
        "marketing",
        "fdas",
        "adcetris",
        "charge",
        "confirmatory",
        "latestage",
        "executive",
        "clay",
        "siegall",
        "call",
        "timeline",
        "detail",
        "future",
        "month",
        "fda",
        "hold",
        "earlystage",
        "companys",
        "trialsimmu132",
        "range",
        "tumor",
        "lung",
        "welleven",
        "stake",
        "agreement",
        "option",
        "antibodydrug",
        "ability",
        "impact",
        "right",
        "doubledigit",
        "net",
        "salesthe",
        "company",
        "feb",
        "dealreporting",
        "grover",
        "bengaluru",
        "editing",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}